Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis
Kosuke Hoashi(Aso Iizuka Hospital), Sohei Harada(University of Tokyo Hospital), Yohei Doi(Fujita Health University), Kazumi Takehana(Japanese Foundation For Cancer Research), Taisuke Enokida(Japanese Foundation For Cancer Research), Masahiro Suzuki(Fujita Health University), Daisuke Ohkushi(Japanese Foundation For Cancer Research), Koichi Takeda(Japanese Foundation For Cancer Research), Aki Sakurai(Fujita Health University), Brian Hayama(Japanese Foundation For Cancer Research)
Cited by 13
Related Papers
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
|The Lancet Infectious Diseases|2017|521
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study
|The Lancet Infectious Diseases|2021|338
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study
|The Lancet Infectious Diseases|2020|328
Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by<i>Enterobacter</i>,<i>Citrobacter</i>or<i>Serratia</i>species: a systematic review with meta-analysis
|Journal of Antimicrobial Chemotherapy|2015|86
Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition
|Clinical Microbiology and Infection|2016|83